Target Name: LIPA
NCBI ID: G3988
Other Name(s): LIPA variant 2 | Cholesterol ester hydrolase | lipase A, lysosomal acid type | LICH_HUMAN | lipase A, lysosomal acid, cholesterol esterase | Acid cholesteryl ester hydrolase | cholesteryl esterase | Lysosomal acid lipase | Lipase A | LAL | Lipase A, lysosomal acid type, transcript variant 1 | Lysosomal acid lipase/cholesteryl ester hydrolase | lysosomal acid lipase | Cholesteryl esterase | Lysosomal acid lipase/cholesteryl ester hydrolase (isoform 1) | acid cholesteryl ester hydrolase | sterol esterase | Lipase A, lysosomal acid, cholesterol esterase | Lipase A, lysosomal acid type, transcript variant 2 | LIPA variant 1 | CESD | Sterol esterase | cholesterol ester hydrolase

LIPA: A Protein Target for Therapeutic Applications

LIPA (LIPA variant 2) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a key regulator of cellular processes that are essential for maintaining tissue health and function. LIPA has also been implicated in a number of diseases, including cardiovascular disease and neurodegenerative disorders. As a result, LIPA has emerged as a promising drug target for a variety of therapeutic applications.

The LIPA protein is composed of several subunits, including a N-terminus, a catalytic C-terminus, and a C-terminal transmembrane region. It has a molecular weight of approximately 40 kDa and is expressed in a variety of tissues, including the brain, heart, and kidneys. LIPA is a critical regulator of cellular processes that are essential for maintaining tissue health and function. It is involved in a number of signaling pathways that are involved in the regulation of cellular processes that are critical for normal development, wound healing, and tissue homeostasis.

One of the key functions of LIPA is its role as a negative regulator of the sodium/calcium gradient (Na/Ca2+ gradient). This gradient is responsible for maintaining the integrity of various cellular processes, including muscle contractions and neurotransmitter release. LIPA helps to regulate the Na/Ca2+ gradient by participating in a number of signaling pathways that are involved in the regulation of ion channels and intracellular signaling pathways.

In addition to its role as a negative regulator of the Na/Ca2+ gradient, LIPA is also involved in the regulation of cellular processes that are critical for normal development and wound healing. LIPA is a critical regulator of the migration of cells during the development of tissues and is involved in the regulation of cell proliferation and differentiation. It is also involved in the regulation of cell adhesion and in the development of tissues that are organized in a specific pattern.

In addition to its role in the regulation of cellular processes, LIPA is also involved in the regulation of cellular signaling pathways. LIPA is a key regulator of the production of various signaling molecules, including neurotransmitters and cytokines. It is involved in the regulation of intracellular signaling pathways that are involved in the regulation of cellular processes that are critical for normal development and function.

The identification of LIPA as a potential drug target has been the subject of extensive research in recent years. LIPA has been shown to be involved in a number of diseases, including cardiovascular disease and neurodegenerative disorders. Researchers have identified a number of potential drug targets for LIPA, including inhibition of its activity as a negative regulator of the Na/Ca2+ gradient and inhibition of its activity as a signaling molecule. In addition, researchers have identified a number of potential drug targets for LIPA that are involved in the regulation of cellular processes that are critical for normal development and function.

In conclusion, LIPA is a protein that is involved in a number of critical cellular processes that are essential for maintaining tissue health and function. Its regulation of the Na/Ca2+ gradient and its role as a negative regulator of cellular signaling pathways make it a promising drug target for a variety of therapeutic applications. Further research is needed to fully understand the mechanisms of LIPA's function and to identify effective strategies for the development of drugs that target LIPA.

Protein Name: Lipase A, Lysosomal Acid Type

Functions: Catalyzes the deacylation of triacylglyceryl and cholesteryl ester core lipids of endocytosed low density lipoproteins to generate free fatty acids and cholesterol

More Common Targets

LIPC | LIPC-AS1 | LIPE | LIPE-AS1 | LIPF | LIPG | LIPH | LIPI | LIPJ | LIPK | LIPM | LIPN | Lipoxygenase | Liprin-beta-1-like | LIPT1 | LIPT2 | LIPT2-AS1 | LITAF | Liver Bile Transporters (LBAT) | LIX1 | LIX1-AS1 | LIX1L | LKAAEAR1 | LKB1-LIP1-SMAD4 complex | LL22NC03-63E9.3 | LLCFC1 | LLGL1 | LLGL2 | LLPH | LMAN1 | LMAN1L | LMAN2 | LMAN2L | LMBR1 | LMBR1L | LMBRD1 | LMBRD2 | LMCD1 | LMCD1-AS1 | LMF1 | LMF2 | LMLN | LMNA | LMNB1 | LMNB2 | LMNTD1 | LMNTD2 | LMNTD2-AS1 | LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988